Insurance Daily News

Medicare Part D Premiums Set for Historic 2027 Increase

A significant shift in the Medicare landscape is set to take effect in 2027, marking the first time since the inception of Medicare Part D that no stand-alone prescription drug plans (PDPs) will be available without a monthly premium for enrollees not receiving low-income subsidies. This change, driven by the conclusion of the Part D Premium Stabilization Demonstration, represents the most substantial single-year premium disruption in the program's history. According to a KFF analysis of Centers for Medicare and Medicaid Services (CMS) data, the average monthly premium for stand-alone PDPs is projected to increase from $34 in 2026 to $51 in 2027, a 50 percent hike.

The disruption stems from the early termination of the stabilization demonstration, which previously provided nearly $9.8 billion in subsidies to plan sponsors over 2025 and 2026. By removing both the subsidy floor and the premium cap simultaneously, the policy change has created a stark financial contrast between stand-alone PDPs and Medicare Advantage prescription drug plans (MA-PDs). While PDP premiums are climbing, MA-PD premiums are projected to drop by 38 percent, falling from $11.32 in 2026 to $7 in 2027. This divergence is largely attributed to the ability of MA-PD sponsors to utilize rebate dollars from Medicare payments to subsidize their drug coverage, a mechanism unavailable to stand-alone PDP providers.

The financial impact on enrollees is widespread. Approximately 10.4 million PDP enrollees—three-fourths of those without low-income subsidies—will face higher monthly costs if they remain in their current plans. Notably, 2.4 million of these individuals will see increases exceeding $50 per month, a sharp contrast to the 38,000 enrollees who faced similar increases in 2026. Beyond premiums, the cost-sharing structure is also tightening. The weighted average deductible for PDP enrollees is expected to rise to $643, and nearly all PDP enrollees will be subject to a deductible in 2027. Furthermore, the shift toward coinsurance models—typically 25 percent for preferred brands and 35 percent for non-preferred drugs—adds a layer of unpredictability to out-of-pocket expenses.

Context: For organizations managing retiree benefits, these shifts necessitate a strategic review of group PDP and Employer Group Waiver Plan (EGWP) arrangements. As the pricing gap between stand-alone plans and Medicare Advantage widens, the competitiveness of employer-sponsored plans may be challenged. Employers should evaluate whether their current offerings remain viable against the individual Medicare market. Additionally, with prescription drug costs already rising due to specialty medications and GLP-1 utilization, the updated actuarial standards for creditable coverage should be verified with an actuary to ensure compliance and avoid potential late enrollment penalties for retirees.

Watch: The upcoming open enrollment period, which concludes on December 7, 2026, will be a critical indicator of how retirees navigate these changes. The widening $42 monthly premium gap between PDPs and MA-PDs is likely to influence enrollment patterns, which will subsequently dictate how employers structure their future group drug benefits. While these changes do not directly impact commercial employer plans, the shifting Medicare landscape will inevitably shape the options retirees select, requiring employers to remain agile in their benefit design.

Why it matters

The elimination of zero-premium Medicare Part D plans and the end of federal stabilization subsidies will force millions of retirees to face significantly higher drug coverage costs, compelling employers to re-evaluate the competitiveness of their retiree benefit structures.

FAQ

Why are zero-premium stand-alone drug plans disappearing in 2027?
The disappearance is due to the end of the Part D Premium Stabilization Demonstration, which provided subsidies and capped premium increases, combined with a structural lack of rebate mechanisms that Medicare Advantage plans use to lower costs.

How much is the average premium for stand-alone PDPs expected to rise?
The average monthly premium is estimated to increase by 50 percent, rising from $34 in 2026 to $51 in 2027.

What is the difference in premium trends between PDPs and MA-PDs?
While stand-alone PDP premiums are projected to rise significantly, MA-PD premiums are expected to drop by 38 percent, from $11.32 in 2026 to $7 in 2027, due to the use of Medicare rebate dollars to buy down costs.

Source: Insurance Business America. See the original source for full details.